PET-centred imaging of ovarian cancer lesions is permitted by 99Zr conjugated to anti-Müllerian-inhibiting substance type II receptor (MISRII) antibodies, while combined radionuclide treatment, which enables patient selection and customised dosimetry, is allowed by therapeutic analogues labelled with 177Lu or 213Bi [129,130]. The gene discussed is AMHR2; the disease is ovarian carcinoma.